Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study

Moro-Sibilot, Denis; Vergnenègre, A.; Smit, Egbert F.; Toy, Elisabeth; Parente, Bárbara; Schmitz, Stephan; Kraaij, Kees; Visseren‐Grul, Carla; Soldatenkova, Victoria; Arellano, Jorge; Leteneux, Claudia

doi:10.1185/03007995.2010.525489

Cited by 16 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Median OS estimates were close to 8 months in 2 studies that reported this information specifically for patients with adenocarcinoma in the second-line setting [18, 22, 27]. Median OS estimates were reported from the time of third-line treatment initiation in 4 studies and median OS ranged from 3.8 (95% CI, 2.6–5.4) to 12.0 months (95% CI, 9.3–14.2) [13, 24, 25]…”

Section: Resultsmentioning

confidence: 98%

“…The proportion of patients who never smoked was highest in the Japanese cohort [13,]. Five studies reported performance status after first-line therapy or at initiation of second-line therapy, with most patients having a Karnofsky Performance Status of 70 or better or an Eastern Cooperative Oncology Group score of 0 or 1 [15, 16, 18, 21, 24, 27]. …”

Section: Resultsmentioning

confidence: 99%

“…Pemetrexed was one of the most commonly prescribed second-line treatments in the studies that included patients treated after its initial approval in 2004 [15–18, 22, 24, 25, 27]. The study conducted in Canada reported that pemetrexed use increased to 70% among treated second-line patients in 2008, when government funding was approved for pemetrexed [20].…”

Section: Resultsmentioning

confidence: 99%

“…In these studies, approximately 30% of patients received third-line treatment (S1 Table). Single-agent chemotherapy accounted for about 50% of third-line treatments in general, and targeted therapy accounted for almost 40% [15–18, 21, 22, 24, 25]. Docetaxel, gemcitabine, vinorelbine, and pemetrexed were the most frequently administered third-line chemotherapies.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

et al. 2017

View full text Add to dashboard Cite

Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for second- and third-line treatment of advanced NSCLC. In light of these approvals, it is valuable to understand the uptake of these new treatments in routine clinical practice and their impact on patient care. A systematic literature search was conducted in multiple scientific databases to identify observational cohort studies published between January 2010 and March 2017 that described second- or third-line treatment patterns and clinical outcomes in patients with advanced NSCLC. A qualitative data synthesis was performed because a meta-analysis was not possible due to the heterogeneity of the study populations. A total of 12 different study cohorts in 15 articles were identified. In these cohorts, single-agent chemotherapy was the most commonly administered treatment in both the second- and third-line settings. In the 5 studies that described survival from the time of second-line treatment initiation, median overall survival ranged from 4.6 months (95% CI, 3.8–5.7) to 12.8 months (95% CI, 10.7–14.5). There was limited information on the use of biomarker-directed therapy in these patient populations. This systematic literature review offers insights into the adoption of novel therapies into routine clinical practice for second- and third-line treatment of patients with advanced NSCLC. This information provides a valuable real-world context for the impact of recently approved treatments for advanced NSCLC.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Pemetrexed is now the preferred second-line treatment for NSCLC in the USA 24. In recent years, clinical researchers had demonstrated the positive effects of this agent in advanced NSCLC, and pemetrexed has gradually become a first-line agent for treatment of the disease 23.…”

Section: Discussionmentioning

confidence: 99%

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Fang¹,

Wang²,

Guo³

et al. 2014

OTT

View full text Add to dashboard Cite

BackgroundThe purpose of this research was to investigate the relationship between epidermal growth factor receptor (EGFR) mutations and the response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).MethodsA total of 266 patients with stage IIIB or IV NSCLC who received platinum-based doublet therapies as first-line chemotherapy were investigated retrospectively, and their clinical data were assessed according to EGFR mutation.ResultsEGFR mutations were identified in 45.5% of patients. There was no significant difference in response rate between EGFR mutation carriers and EGFR wild-type carriers (P=0.484). Among the patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type, however, those with EGFR mutations responded better to treatment than EGFR wild-type patients (46.2% versus 20.8%, P=0.043). The disease control rate associated with pemetrexed-based treatments was higher than for vinorelbine-based therapies in EGFR mutation patients (P=0.001). EGFR mutation was found in patients with longer progression-free survival and median survival time, and improved 1-year and 2-year overall survival when compared with EGFR wild-type patients (6.1 versus 5.0 months, P=0.004; 18.9 versus 13.8 months, P=0.001; 81.0% versus 63.4%, P=0.002; and 33.9% versus 22.8% P=0.044, respectively). Patients with the EGFR exon 19 mutation had longer progression-free survival than those with EGFR exon 21 mutation (P=0.007). Multivariate analysis showed that the response to first-line chemotherapy and the presence of EGFR mutations were independent prognostic factors in patients with advanced NSCLC.ConclusionOur data showed that the presence of EGFR mutations meant longer survival times for patients with advanced NSCLC who received platinum-based doublet first-line chemotherapy, especially in those with the exon 19 deletion mutation. Among KRAS wild-type patients, those with EGFR mutation responded better to first-line chemotherapy than EGFR wild-type patients.

show abstract

Identifying Subsequent Therapies in Patients with Advanced Non–Small Cell Lung Cancer and Factors Associated with Overall Survival

et al. 2016

View full text Add to dashboard Cite

show abstract

Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study

Cited by 16 publications

References 30 publications

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Identifying Subsequent Therapies in Patients with Advanced Non–Small Cell Lung Cancer and Factors Associated with Overall Survival

Contact Info

Product

Resources

About